Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a leader in the diabetes technology industry with a global presence and strong revenue growth potential. Their focus on innovation, worldwide reach, and differentiated technology is expected to continue driving profitability, while their track record of positive clinical outcomes and strong patent portfolio provide a competitive advantage. Their expansion into new markets and commitment to developing new products, along with a highly-rated stock and experienced leadership, make them a solid investment choice.

Bears say

Minimed Group is well-positioned to capitalize on a significant total addressable market for diabetes management solutions, but with only a ~7% penetration rate, there is significant room for competition to enter and potentially erode MiniMed's market share. Additionally, the company's reliance on intensive insulin therapy means it may face challenges as lifestyle management and alternative treatments become more popular. While MiniMed has a strong, unlevered balance sheet, their margins are projected to decline in the near term due to product launches and clinical trials, which could impact profits and cash flow.

MMED has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 11 analysts, MMED has a Buy consensus rating as of Aug 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.